P176: Garcinol as a new therapeutic option for chondrosarcoma
FAU own research funding: EFI / IZKF / EAM ...
Start date : 01.06.2025
End date : 31.05.2026
Project details
Scientific Abstract
Chondrosarcomas are malignant bone tumors, which do not respond to existing chemo- and radiotherapy. Preliminary studies could show that the the natural compound Garcinol strongly reduces proliferation and colony formation of these tumor cells. Additionally, Garcinol could re-sensitize chondrosarcoma cells to the chemotherapeutic Cisplatin. We therefore want to investigate the role of Garcinol as a new therapeutic option for chondrosarcoma.
Involved:
Contributing FAU Organisations:
Interdisziplinäres Zentrum für Klinische Forschung (IZKF)
Lehrstuhl für Biochemie und Molekulare Medizin
